Navigation Links
FDA Gives Nod to First Drug for Diabetic Eye Disease

FRIDAY, Aug. 10 (HealthDay News) -- The U.S. Food and Drug Administration on Friday gave its approval to the drug Lucentis as a treatment for diabetic macular edema (DME), making it the first medicine approved for the ailment.

According to the U.S. Centers for Disease Control and Prevention, DME occurs when fluid enters the macula, the central part of the eye's retina. This causes the macula to expand, blurring vision. Because up to 26 million Americans have either type 1 or type 2 diabetes, this eye condition is a major source of new-onset vision loss, the FDA said. In 2010, 3.9 million diabetic adults had trouble with their vision.

Laser surgery has been the only approved treatment until now for DME.

"Diabetes is a major public health issue in our country, and all patients with diabetes are at risk of developing diabetic macular edema," Dr. Renata Albrecht, director of the division of transplant and ophthalmology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "Today's approval represents a major development for the treatment of people whose vision is impaired by DME as a complication of their disease."

Lucentis (ranibuzumab injection) is manufactured by Genentech and given via a monthly injection from a health care professional. It is meant to be taken along with proper blood sugar control, the FDA said. The drug has previously been approved to treat wet age-related macular degeneration, another major cause of vision loss in older individuals, and a condition called "macular edema following retinal vein occlusion," where a blockage of veins in the retina cause fluid to leak into the macula.

According to the FDA, Friday's approval was based on two studies involving 759 patients with DME who were treated and then followed for three years. The studies found that between 34 percent and 45 percent who received Lucentis gained at least three lines of vision on the standard eye chart test, compared to 12 percent to 18 percent of those who did not get the drug.

Side effects included bleeding in the tissue lining the inner part of the eyelids, eye pain, "floaters" and increased pressure within the eye.

More information

For more on diabetes-linked eye disease, including DME, head to the U.S. National Eye Institute.

-- E.J. Mundell

SOURCE: Aug. 10, 2012, news release, U.S. Food ad Drug Administration

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Gives Green Light to Publish Controversial Bird Flu Research
2. Image share project gives patients and physicians anytime, anywhere access to medical images
3. Procedure gives patients with A-fib who cant take blood thinners alternative to reduce stroke
4. UMD team gives drug dropouts a second chance
5. FDA Panel Gives Blessing to New Weight-Loss Drug
6. Amazon Tribe Gives Clues to Heart-Healthy Lifestyles
7. Killer stainless steel: New process gives icon of cleanliness antibacterial coating
8. Aurora Dentist Gives Patients Big Savings With Teeth in a Day Implants
9. OC Firm Gives Back to Young Athletes
10. Study Gives First Evidence That Adult Human Lungs Can Regrow
11. FDA Gives Nod to New Breast Cancer Drug
Post Your Comments:
Related Image:
FDA Gives Nod to First Drug for Diabetic Eye Disease
(Date:10/13/2015)... ... October 13, 2015 , ... ... announced today their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user ... Green Valley Ranch and will unite customers, partners, WennSoft team members and sponsors ...
(Date:10/13/2015)... ... ... Scientists in Seattle and Vancouver compared the diagnostic value of lung fluid ... Mesothelioma has just posted an article on the new research. Click here to ... University of British Columbia found that certain genetic alterations were seen just as often ...
(Date:10/13/2015)... GA (PRWEB) , ... October 13, 2015 , ... ... nonprofit promoting the establishment of telemedicine programs in communities throughout Georgia, along with ... announce the collective schedule for their regional telehealth summits for Fall 2015. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... new School of Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from ... education that has spanned four decades. , Dr. McLeod’s long and successful nursing ...
(Date:10/13/2015)... ... October 13, 2015 , ... Local Gold’s Gym franchise owner, ... Conference on August 26. Berry, who owns and operates Gold's Gym Cheyenne ... growing Gold’s Gyms in the United States. A brand leader in global fitness, Gold’s ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015   Rosa & Co. ... in Quantitative Systems Pharmacology (QSP)/ PhysioPD™ , today announced ... lead a workshop at the QSP Congress Meeting ... Boston, MA.  The conference focuses on ... development.  Dr. Friedrich,s workshop is entitled "Using Mechanistic Physiological ...
(Date:10/13/2015)... World Thrombosis Day Interactive Infographic ...   --> World Thrombosis Day Interactive ... promote vital global awareness of thrombosis, its causes, ... the formation of potentially deadly blood clots in ... thromboembolism (VTE) - or the artery (arterial thrombosis) [1] ...
(Date:10/12/2015)... Apheresis is an invasive process that involves ... other components from whole blood. In this procedure, the blood ... apheresis machine or a blood cell separator. The apheresis equipment ... blood components. A selected part of the blood is removed, ... the patient. It involves the use of devices and disposables ...
Breaking Medicine Technology: